Patents Assigned to MAIA Pharmaceuticals, Inc.
-
Patent number: 11918622Abstract: Ready-to-use liquid bivalirudin compositions, methods of using the ready-to-use bivalirudin compositions, and methods of preparing the ready-to-use liquid bivalirudin compositions are provided herein. The liquid ready-to-use bivalirudin compositions comprise a pharmaceutically acceptable amount of bivalirudin.Type: GrantFiled: November 30, 2022Date of Patent: March 5, 2024Assignee: MAIA PHARMACEUTICALS, INC.Inventor: Srikanth Sundaram
-
Patent number: 11903993Abstract: Ready-to-use liquid bivalirudin compositions, methods of using the ready-to-use bivalirudin compositions, and methods of preparing the ready-to-use liquid bivalirudin compositions are provided herein. The liquid ready-to-use bivalirudin compositions comprise a pharmaceutically acceptable amount of bivalirudin.Type: GrantFiled: November 30, 2022Date of Patent: February 20, 2024Assignee: MAIA PHARMACEUTICALS, INC.Inventor: Srikanth Sundaram
-
Patent number: 11752164Abstract: The present disclosure relates to ready-to-use liquid aqueous bortezomib compositions bortezomib and pharmaceutical excipients. Other aspects include methods of preparing such ready-to-use liquid aqueous bortezomib compositions, and methods of using such ready-to-use liquid bortezomib compositions in therapeutic applications.Type: GrantFiled: March 22, 2023Date of Patent: September 12, 2023Assignee: MAIA PHARMACEUTICALS, INC.Inventors: Srikanth Sundaram, Daniel Charles Stewart
-
Patent number: 11737983Abstract: Disclosed herein are solid compositions that comprise sincalide and are storage stable and which lack a buffer, and optionally, also lack a surfactant/solubilizer, wherein such compositions are storage stable. Also disclosed herein are liquid compositions that comprise sincalide, wherein such compositions are storage stable, and may lack buffer and/or surfactant/solubilizer. Also provided are methods of making and administering the solid or liquid storage stable compositions to a patient in need of, e.g., for the treatment, prevention, and/or diagnosis of gall bladder- and/or pancreatic disorders; or other diagnostic imaging.Type: GrantFiled: April 1, 2022Date of Patent: August 29, 2023Assignee: MAIA PHARMACEUTICALS, INC.Inventor: Srikanth Sundaram
-
Patent number: 11679119Abstract: The present disclosure relates to ready-to-use liquid aqueous bortezomib compositions bortezomib and pharmaceutical excipients. Other aspects include methods of preparing such ready-to-use liquid aqueous bortezomib compositions, and methods of using such ready-to-use liquid bortezomib compositions in therapeutic applications.Type: GrantFiled: September 23, 2022Date of Patent: June 20, 2023Assignee: MAIA PHARMACEUTICALS, INC.Inventors: Srikanth Sundaram, Daniel Charles Stewart
-
Patent number: 11672813Abstract: The present disclosure relates to ready-to-use liquid aqueous bortezomib compositions bortezomib and pharmaceutical excipients. Other aspects include methods of preparing such ready-to-use liquid aqueous bortezomib compositions, and methods of using such ready-to-use liquid bortezomib compositions in therapeutic applications.Type: GrantFiled: September 23, 2022Date of Patent: June 13, 2023Assignee: MAIA PHARMACEUTICALS, INC.Inventors: Srikanth Sundaram, Daniel Charles Stewart
-
Patent number: 11596736Abstract: A medication delivery patch that is applied to the skin and activated to deliver a medication or other fluid into or through the skin. The patch may be completely mechanically driven, with no electronic components, for low cost, safety, and reliability. Pressing an activation button may set in motion a sequence of mechanical events that result in a needle exiting the patch into the skin of the user, and flow of fluid from an internal pouch in the patch into the user. When delivery is complete, another sequence of mechanical events may occur to retract the needle from the skin and stop the flow of fluid, and to show a visible indicator that delivery is complete. The patch may contain a fluid channel, such as a microfluidic channel, that controls the rate and time of delivery; this channel can be configured or selected for different medications or use cases.Type: GrantFiled: August 10, 2022Date of Patent: March 7, 2023Assignee: Maia Pharmaceuticals, Inc.Inventor: Gina G. Stetsko
-
Patent number: 11318100Abstract: Disclosed herein are solid compositions that comprise sincalide and are storage stable and which lack a buffer, and optionally, also lack a surfactant/solubilizer, wherein such compositions are storage stable. Also disclosed herein are liquid compositions that comprise sincalide, wherein such compositions are storage stable, and may lack buffer and/or surfactant/solubilizer. Also provided are methods of making and administering the solid or liquid storage stable compositions to a patient in need of, e.g., for the treatment, prevention, and/or diagnosis of gall bladder- and/or pancreatic disorders; or other diagnostic imaging.Type: GrantFiled: August 9, 2021Date of Patent: May 3, 2022Assignee: MAIA Pharmaceuticals, Inc.Inventor: Srikanth Sundaram
-
Patent number: 11110063Abstract: Disclosed herein are solid compositions that comprise sincalide and are storage stable and which lack a buffer, and optionally, also lack a surfactant/solubilizer, wherein such compositions are storage stable. Also disclosed herein are liquid compositions that comprise sincalide, wherein such compositions are storage stable, and may lack buffer and/or surfactant/solubilizer. Also provided are methods of making and administering the solid or liquid storage stable compositions to a patient in need of, e.g., for the treatment, prevention, and/or diagnosis of gall bladder- and/or pancreatic disorders; or other diagnostic imaging.Type: GrantFiled: April 20, 2018Date of Patent: September 7, 2021Assignee: MAIA Pharmaceuticals, Inc.Inventor: Srikanth Sundaram